This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Palliative care, which did not include biologic therapy, was compared with adalimumab, etanercept, or infliximab.
Location/setting
UK/secondary care.
Methods

Analytical approach:
The analysis used an updated version of a published probabilistic cohort model. A lifetime horizon was considered and the authors reported that the perspective of the UK NHS was adopted.
Effectiveness data:
A systematic review and evidence synthesis were undertaken for this study and were published separately. The effectiveness data were from a variety of sources including published studies, expert opinion, and manufacturers' estimates. For example, the rate of withdrawal from biologics was estimated from a meta-analysis, and disease progression measured by the Health Assessment Questionnaire (HAQ) for those on palliative care was from the Norfolk Arthritis Register. The main measure of effectiveness was the probability of response measured using the Psoriatic Arthritis Response Criteria (PsARC).
Monetary benefit and utility valuations:
The utility values were based on data from one of the manufacturers, who carried out linear regression on the European Quality of life (EQ-5D) utility scores versus HAQ and Psoriasis Area Severity Index (PASI) scores, from participants in randomised controlled trials.
Measure of benefit:
Quality-adjusted life-years were the summary measure of benefit and they were discounted at an annual rate of 3.5%.
Cost data:
The economic analysis included pharmaceutical costs (drugs, administration, and monitoring) and the costs of treatments for arthritis and psoriasis. Pharmaceutical costs were from the British National Formulary, and arthritis and
